Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus VIBRAMYCIN.
OXYTETRACYCLINE HYDROCHLORIDE vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic